Navigation Links
New Hope for Treatment of Pancreatic Cancer
Date:9/25/2009

By inhibiting key enzyme, researchers shrank tumors, prolonged survival in mice

FRIDAY, Sept. 25 (HealthDay News) -- Inhibiting the action of an enzyme called TAK-1 reverses pancreatic cancer resistance to chemotherapy, a finding that could lead to the development of a new way to treat the disease, researchers say.

Pancreatic cancer is resistant to every currently available anti-cancer treatment.

"During the past few years we have been studying the role played by a cytokine or regulatory protein called transforming growth factor-beta [TGFbeta] in the development of pancreatic cancer. Recently we focused our attention on a unique enzyme activated by TGFbeta, TAK-1, as a mediator for this extreme drug resistance" in pancreatic cancer, study author Dr. Davide Melisi said in a news release from the European Cancer Organization.

He and his colleagues developed a TAK-1 inhibitor and tested it on its own and in combination with the anti-cancer drugs gemcitabine, oxaliplatin and SN-38 (a metabolite of the anti-cancer drug irinotecan) in pancreatic cancer cell lines. They also tested the TAK-1 inhibitor combined with gemcitabine against pancreatic cancer in mice.

"The use of this TAK-1 inhibitor increased the sensitivity of pancreatic cells to all three chemotherapeutic drugs," Melisi said.

"By combining it with classic anti-cancer drugs, we were able to use doses of drugs up to 70 times lower in comparison with the control to kill the same number of cancer cells. In mice, we were able to reduce significantly the tumor volume, to prolong the mice survival, and to reduce the toxicity by combining the TAK-1 inhibitor with very low doses of a classic chemotherapeutic drug, gemcitabine, that would have been ineffective otherwise," Melisi added.

The study was scheduled for presentation Sept. 24 at the joint meeting of the European Cancer Organization and the European Society for Medical Oncology in Berlin.

"This is the first time that TAK-1 has been indicated as a relevant target for the treatment of a solid tumor and that it is a valid approach to reverting the intrinsic drug resistance of pancreatic cancer," Melisi stated. "The TAK-1 inhibitor used in this study is an exciting drug that warrants further development for the treatment of pancreatic cancer."

More information

The American Cancer Society has more about pancreatic cancer.



-- Robert Preidt



SOURCE: European Cancer Organization, news release, Sept. 24, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. New Treatment May Beat Melanoma
2. Lifestyle interventions in the prevention and treatment of cancer
3. M. D. Anderson examines use of toad venom in cancer treatment
4. Michael J. Fox Foundation Commits Up to $5 Million to Help Advance Neurotrophic Factors From Promise to Reality As Parkinsons Treatment
5. Shady Grove Fertility Center Presents 5K Fundraising Race to Help Families Afford Fertility Treatment or Adoption
6. Study reveals 2/3 of prostate cancer patients do not need treatment
7. Discovery could improve hepatitis C treatment
8. Targeted heat therapy offers new standard treatment option for soft tissue sarcoma
9. National Autism Center Releases Groundbreaking Report on Autism Treatments
10. Women's Pelvic Organ Prolapse and Incontinence Guide Informs, Outlines Treatments
11. FDA Advisory Committee Unanimously Recommends Approval of XIAFLEX(TM) for Treatment of Dupuytrens Disease
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New Hope for Treatment of Pancreatic Cancer
(Date:12/9/2016)... ... December 09, 2016 , ... Flottman ... and outserts. As a means of expanding capabilities Flottman has added a ... to individually code professional inserts (PIs) and patient package inserts (PPIs) that will ...
(Date:12/9/2016)... ... December 09, 2016 , ... Mediaplanet today announces distribution of ... while encouraging readers to sign up as an organ donor for the 123,000 people ... , An organ donor can save up to 8 saves through organ donation and ...
(Date:12/8/2016)... ... December 08, 2016 , ... The West ... January 1, 2017. The name change aligns the entire company with its ... health care quality. , “We are very proud of the achievements associated with ...
(Date:12/8/2016)... JENNERSVILLE, Pa. (PRWEB) , ... December 08, 2016 ... ... Penn Medicine Southern Chester County, a Property owned by an affiliate of Seavest, ... 72,000 square foot Penn Medicine Southern Chester County ambulatory care center (ACC) was ...
(Date:12/8/2016)... ... December 08, 2016 , ... Premier Fitness Camp (PFC) ... , the ultimate weight loss and wellness program, at their world headquarters of Omni ... provide immediate and long-term results to anyone seeking weight loss, personal development, a healthy ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... NEW YORK , Dec. 8, 2016 ... ... such as reducing loss of blood during surgeries, lowering the ... surgeries, and decreasing risks of SSIs. The patient warming systems ... and intravascular warming systems.These benefits in turn reduce the stay ...
(Date:12/8/2016)... -- KEY FINDINGS North America ... in 2016 and is expected to continue in the ... large number of surgical procedures that are taking place ... the patient temperature management market.) Patient warming and cooling ... blood during surgeries, lowering the risks of neurological disorders ...
(Date:12/8/2016)... Research and Markets has announced the addition of the "Endodontic Supplies - ... ... worldwide markets for Endodontic Supplies in US$ Thousand. The report provides separate comprehensive ... , Europe , Asia-Pacific , ... forecasts are provided for the period 2015 through 2022. Also, a six-year historic ...
Breaking Medicine Technology: